Viatris | VTRS

Stock Price
10.50
Daily Change
0.17 1.65%
Monthly
20.00%
Yearly
-6.87%
Q3 Forecast
10.41

Peers Price Chg Day Year Date
Celltrion 169,000.00 -1,200.00 -0.71% -11.61% Sep/05
Cspc Pharmaceutical 11.19 0.36 3.32% 140.13% Sep/05
Sino Biopharmaceutical 8.91 0.52 6.20% 183.76% Sep/05
Zhangzhou Pientzehuang Pharmaceutical 203.87 0.94 0.46% 0.69% Sep/05
Kangmei Pharma 2.03 0 0% 15.34% Sep/05
Adcock Ingram Holdings 7,187.00 -13.00 -0.18% 10.77% Sep/05
Divis Laboratories Ltd 6,009.00 -124.50 -2.03% 16.96% Sep/05
Knight Therapeutics 6.44 0 0% 14.18% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Malin Corporation 8.00 0 0% 29.03% Sep/01
Medical Developments International 0.58 -0.01 -0.86% 36.90% Sep/05
Neuren Pharmaceuticals 20.48 0.50 2.50% 51.03% Sep/05
Organigram Holdings 2.28 0.08 3.64% -4.20% Sep/05
Pharma Mar 88.40 -2.80 -3.07% 116.88% Sep/05
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
Laboratorios Farma 59.65 -0.10 -0.17% -26.18% Sep/05
Sartorius 193.20 4.90 2.60% -23.42% Sep/06
Tilray 1.64 0.06 3.80% -25.45% Sep/05
Viatris 10.50 0.17 1.65% -6.87% Sep/05

Indexes Price Day Year Date
US500 6481 -20.59 -0.32% 19.84% Sep/05

Viatris Inc traded at $10.50 this Friday September 5th, increasing $0.17 or 1.65 percent since the previous trading session. Looking back, over the last four weeks, Viatris gained 20.00 percent. Over the last 12 months, its price fell by 6.87 percent. Looking ahead, we forecast Viatris Inc to be priced at 10.41 by the end of this quarter and at 10.16 in one year, according to Trading Economics global macro models projections and analysts expectations.

Viatris Inc. is a global healthcare company. The Company''s segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.